5 Under-35 Biotech Innovators Changing Healthcare
From AI-designed viruses to age-reversal tech, meet the young minds reshaping medicine.
1Tackling maternal mortality
Paschal Kija, 28, developed the $70 Mkanda Salama device to treat postpartum hemorrhage, which causes 29% of maternal deaths in Tanzania. Clinical trials show it stops bleeding in 73% of cases within 20 minutes. The low-cost wrap combines traditional knowledge with modern medical design, addressing a critical gap in maternal healthcare across developing nations.
2Brain-friendly electrodes
Xiao Yang's kirigami-inspired neural interfaces mimic natural neuron structures. Her 34-year-old team created ultra-thin, flexible electrodes that reduce tissue damage during implantation. The honeycomb-shaped arrays enable precise brain activity monitoring while minimizing inflammation—a major advancement for treating Parkinson's and epilepsy.
3Personalized gene therapy
Sarah Grandinette, 26, pioneered a bespoke treatment for infant KJ's rare genetic disorder. After testing 15 gene-editing approaches on lab-grown cells and animal models, her team successfully corrected the DNA mutation. KJ showed improvement within weeks of receiving the therapy, marking a milestone in precision medicine for genetic diseases.
4Age reversal breakthrough
Yuancheng Lu's cellular reprogramming therapy restored vision in blind mice by resetting aged cells to embryonic-like states. Now in human trials at Life Biosciences, this approach could treat macular degeneration. The 34-year-old's work represents the most promising near-term application of longevity science in clinical practice.
5AI-generated medicine
Samuel King, 27, demonstrated that AI-designed bacteriophages can self-replicate and target specific bacteria. His team synthesized these viral blueprints into functional DNA strands, proving AI can create viable biological systems. Future applications may include precision antibiotics and environmental bioremediation agents.
6The selection process
MIT's 35 Under 35 list identifies researchers whose work shows exceptional technical merit and real-world impact potential. This year's biotech cohort was selected from 300+ nominations by a panel of scientists and industry experts. Criteria included novelty of approach, scalability, and potential to address UN Sustainable Development Goals.
7Funding landscape
These innovations benefited from $2.3B in global biotech VC funding in 2023, with longevity tech attracting 40% growth. However, African innovators like Kija receive less than 3% of life sciences investment. The disparity highlights untapped potential in emerging markets for high-impact, cost-effective solutions.
8What's next
Within 5 years, these technologies could yield 3 FDA-approved therapies and 2 new diagnostic platforms. The work exemplifies how young scientists are accelerating the biotech revolution—blazing trails from lab benches to patient bedsides while redefining healthcare's future.
Original article: MIT Technology Review — 5 Under-35 Biotech Innovators Changing Healthcare